cas 916420-27-4|| where to buy tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

Nom du produit:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

IUPAC Name:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

: CAS：916420-27-4; Formule moléculaire：C12H15Cl2N3O2; Pureté：95%+

Unité d'emballage	Stock disponible	Prix($)
CM104183-5g	in stock	ƎȺ
CM104183-10g	in stock	ǶŵǶ
CM104183-25g	in stock	ũǜũ
CM104183-100g	in stock	țưǊ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 916420-27-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:916420-27-4; Formule moléculaire:C12H15Cl2N3O2; Point de fusion:-; Code SMILES:CC(C)(C)OC(=O)N1CCC2=C(Cl)N=C(Cl)N=C2C1; Densité:

: Numéro de catalogue:CM104183; Poids moléculaire:304.17; Point d'ébullition:; N° Mdl:MFCD09025732; Stockage:

: Adagrasib; Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.